News

C&R Research has signed a contract to conduct a Phase 1 clinical trial for 'PHI-501', an investigational drug being developed…

C&R Research announced that it has finalized a dividend of KRW 10 per share, totaling KRW 570 million, for 56,725,420…

Growth Research assessed that C&R Research has the potential to expand its global influence through its Clinical Research Organization (CRO)…

C&R Research selected as a "2024 Best Work-Life Balance Company" in Korea!   "2024 Best Work-Life Balance Company" was newly…

C&R Healthcare Global (Thailand) Co., Ltd., the Thai subsidiary of C&R Research, and KIMCo(Korea Innovative Medicines Consortium) signed an MOU…

C&R Research continues to demonstrate its strength as a leading Contract Research Organization (CRO) by maintaining strong performance growth this…

C&R Research, providing global clinical trial services, plans to strengthen its strategic relationships with various pharmaceutical and biotech companies in…

C&R Research announced through this disclosure that it will transfer its IT solution lineup to its subsidiary, Trial Informatics, allowing…

C&R Research, AbClon, and GCCL signed an MOU to ‘Develop Analytical Methods for Biopharmaceuticals’.   Moon-Tae Yoon, CEO of C&R…

The Bestian Foundation hosts the 'The 25th Medical Device Innovation Seminar' on 11/6 2PM in the OK-MPS Validation Center 3F…